CLINICAL TRIALS PROFILE FOR LY3556050

Clinical Trials for LY3556050

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT04156750 ↗	A Study of LY3556050 in Healthy Participants	Completed	Eli Lilly and Company	Phase 1	The main purpose of this study is to learn more about the safety of LY3556050 after it is given by mouth to healthy participants. Blood tests will be performed to check how much LY3556050 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive multiple doses of LY3556050 or placebo and will remain in the study for up to 31 days.
NCT04627038 ↗	Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis	Completed	Eli Lilly and Company	Phase 2	This study is being done to test the safety and efficacy of LY3556050 for the treatment of osteoarthritis pain. This trial is part of the chronic pain master protocol (H0P-MC-CPMP) which is a protocol to accelerate the development of new treatments for chronic pain.
NCT04707157 ↗	Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain	Recruiting	Eli Lilly and Company	Phase 2	This study is being done to test the safety and efficacy of the study drug LY3556050 for the treatment of diabetic peripheral neuropathic pain. This trial is part of the chronic pain master protocol (H0P-MC-CPMP) which is a protocol to accelerate the development of new treatments for chronic pain.
NCT04874636 ↗	Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Chronic Low Back Pain	Recruiting	Eli Lilly and Company	Phase 2	This study is being done to test the safety and efficacy of the study drug LY3556050 for the treatment of chronic low back pain. This trial is part of the chronic pain master protocol (H0P-MC-CPMP) which is a protocol to accelerate the development of new treatments for chronic pain.
NCT05341102 ↗	A Study of Single and Repeated Doses of LY3556050 in Healthy Participants	Completed	Eli Lilly and Company	Phase 1	The main purpose of this study is to conduct blood tests to measure how much LY3556050 is in the bloodstream and to determine if any age, gender, or food effects exist. The study will also evaluate the safety of LY3556050. This is a 2-part study. In Part 1, single increasing doses of LY3556050 will be given orally and participants will be confined for a 5-day period. In Part 2, multiple increasing doses of LY3556050 will be given orally and participants will be confined for a 14-day period.
NCT05615467 ↗	A Study of Effect of LY3556050 on Metformin in Healthy Participants	Not yet recruiting	Eli Lilly and Company	Phase 1	The main purpose of this study is to evaluate how much Metformin gets into the bloodstream and how long the body takes to get rid of it when it is administered orally in combination with LY3556050 in healthy participants. Iohexol will be administered to evaluate kidney function. Each enrolled participant will remain in the study for up to 7 weeks including the screening period.

Clinical Trial Conditions for LY3556050

Condition Name

Condition Name for
Intervention	Trials
Healthy	3
Chronic Low-back Pain	1
Diabetic Peripheral Neuropathic Pain	1
Osteoarthritis	1

Condition MeSH

Condition MeSH for
Intervention	Trials
Chronic Pain	2
Osteoarthritis	1
Low Back Pain	1
Back Pain	1

Clinical Trial Locations for LY3556050

Trials by Country

Trials by Country for
Location	Trials
United States	55
Puerto Rico	3
Singapore	1

Trials by US State

Trials by US State for
Location	Trials
Texas	4
Ohio	4
Connecticut	3
Florida	3
Illinois	3

Clinical Trial Progress for LY3556050

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 2	3
Phase 1	3

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Completed	3
Recruiting	2
Not yet recruiting	1

Clinical Trial Sponsors for LY3556050

Sponsor Name

Sponsor Name for
Sponsor	Trials
Eli Lilly and Company	6

Sponsor Type

Sponsor Type for
Sponsor	Trials
Industry	6